Latest News

mTOR pathway inhibitors are key drugs for the treatment of many tumor types, however, there are no predictive biomarkers in clinical use. Here, we performed a molecular and immunohistochemical characterization of key mTOR pathway components in a series of 105 renal cell carcinoma (RCC) patients treated with rapalogs, aimed at identifying markers of treatment response. […]

Recent publications evaluating cytoreductive nephrectomy in the era of targeted therapy emphasize the importance of patient selection. We reviewed the predictive role of genetic alterations in patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy. Studies evaluating the association between genetic alterations and outcomes following systemic treatment for mRCC include mainly patients after cytoreductive […]

To perform a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating risk-benefit for adjuvant postoperative treatments in high-risk renal cell carcinoma by assessing reported disease-free survival (DFS), overall survival (OS), toxicity, and quality of life. A literature search was performed in PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials […]

Androgen-deprivation therapy (ADT) has been the mainstay of treatment for metastatic prostate cancer since the first report of its hormonal dependence in the 1940s. Since 2015, the addition of docetaxel and the addition of abiraterone to ADT have confered significant overall survival benefit in men with metastatic castration-naïve prostate cancer (mCNPC). The shift of these […]

Several blood protein biomarkers have been associated with prostate cancer (PrCa) risk. However, most studies assessed only a small number of biomarkers and/or included a small sample size. To identify novel protein biomarkers of PrCa risk, we studied 79,194 cases and 61,112 controls of European ancestry, included in the PRACTICAL/ELLIPSE consortia, using genetic instruments of […]

Prostate cancer (PCa) is one of the most common primary malignancies in humans and the second leading cause of cancer-specific mortality among Western males. Computer-aided detection (CAD) systems have been developed for accurate and automated PCa detection and diagnosis, but the diagnostic accuracy of different CAD systems based on magnetic resonance imaging (MRI) for PCa […]

Prostate cancer has a high prevalence and mortality, being the most diagnosed urologic cancer. Prostatic magnetic resonance imaging showed high sensitivity in the detection of clinically significant neoplasia and agreement with the Gleason score. Therefore, we attempted to evaluate the diagnostic accuracy of the prostate imaging reporting and data system, using biopsy and prostatectomy as […]

The main issue concerning localized prostate cancers is the lack of a suitable marker which could help patients’ stratification at diagnosis and distinguish those with a benign disease from patients with a more aggressive cancer. Circulating Tumor Cells (CTC) are spread in the blood by invasive tumors and could be the ideal marker in this […]

Phillip Koo: Hi, this is Phillip Koo and welcome again to another lecture in our Society of Nuclear Medicine and Molecular Imaging series on prostate cancer imaging and therapy. Today we’re extremely fortunate to have with us Dr. Andrei Iagaru from Stanford University. He’s a professor of radiology at Stanford and also chief of nuclear […]